No End in Sight for Actos Bladder Cancer Debate
The last two years have been difficult for each Actos lawyer, users of the medication as well as the drug manufacturer, Takeda Pharmaceuticals, all of which have been closely watching the Actos bladder cancer debate that has been swirling around the medication.
Since 2010, Takeda Pharmaceuticals has been under intense pressure from the Federal Drug Administration (FDA) and its users who claim the company failed to appropriately warn the public about the risks, particularly Actos bladder cancer, associated with taking the drug. These accusations have led to FDA investigations and multiple Actos lawsuits.
Actos is a drug that helps diabetes patients regulate their blood levels. It was approved for use in 1999, but was met with concern from the FDA as soon as 2005. One of the largest issues with Actos use is Actos bladder cancer.
FDA Turns Up the Heat on Actos Bladder Cancer Debate
In 2005, a PROspective PioglitAzone Clinical Trial in Macro Vascular Events showed that, following three years of study, Actos was more likely to cause bladder cancer than similar drugs used to treat similar issues. The FDA launched an investigation into the prevalence of Actos bladder cancer in 2010.
In June of 2011, the FDA issued an Actos bladder cancer warning. Not long after, the European Medicines Agency removed the product from the market. In 2011, the FDA responded by approving a new Actos warning label. The label, which was also approved for ActoPlus Met and Duetact, urges patients to seek physician council if they experience Actos bladder cancer symptoms.
The new label encourages people with Type 2 diabetes to look other blood sugar control drugs if at all possible.
Actos Lawsuits Ramp Up
Inquiries of an Actos lawyer seems to have increased during this short time. The information about Actos bladder cancer that has been collected by the FDA, the American Diabetes Association and the European Medicines Agency has alarmed many individuals about the drug.
The attention the FDA is paying to the drug and the hundreds of individuals who have claimed they’ve experienced some Actos side effect, namely Actos bladder cancer, has created a surge in Actos lawsuits. Hundreds more people are expected to contact an Actos lawyer within the next year and a multidistrict litigation (MDL) is possible.
Though 10 years have passed since the FDA approved Actos to treat diabetes, the debate about Actos is far from over.